[1] 中国医院药学杂志, 网络首发时间, 2020-04-08, 网络首发地址: http://kns.cnki.net/kcms/detail/42.1204.r. 20200407.1419.002.html.
[2] 纪晓光, 赵艳红, 张敏, 等. 阿比多尔抗SARS病毒的体外实验研究[J]. 解放军药学学报, 2004, 20(4):274-276. doi:  10.3969/j.issn.1008-9926.2004.04.012
[3] BORISKIN Y S, LENEVA I A, PÉCHEUR E I, et al. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion[J]. Curr Med Chem,2008,15(10):997-1005. doi:  10.2174/092986708784049658
[4] BLAISING J, POLYAK S J, PÉCHEUR E I. Arbidol as a broad-spectrum antiviral: an update[J]. Antiviral Res,2014,107:84-94. doi:  10.1016/j.antiviral.2014.04.006
[5] 周楚铭, 王媛, 赵立. 多国新型冠状病毒感染病死率及其抗病毒方案差异的比较分析[J]. 中国临床药理学杂志, 2020, 36(22):3869-3872.
[6] 刘晓. 盐酸阿比朵尔药代动力学研究[D]. 沈阳: 沈阳药科大学, 2009.
[7] SONG J H, FANG Z Z, ZHU L L, et al. Glucuronidation of the broad-spectrum antiviral drug arbidol by UGT isoforms[J]. J Pharm Pharmacol,2013,65(4):521-527. doi:  10.1111/jphp.12014
[8] HOU Y D, YANG X K, LI Y Y, et al. Cloning of human leukocyte interferon gene and its expression in E. coli[J]. Acta Acadmiak medsci,1982,6:327-335.
[9] 陈岷, 童荣生, 边原, 等. 皮下注射α-干扰素治疗2019年新型冠状病毒肺炎的循证快速评估[J]. 医药导报, 2020, 39(4):483-488.
[10] 陈永坤, 朱闻斐, 舒跃龙. 干扰素诱导的跨膜蛋白抗病毒作用的研究进展[J]. 病毒学报, 2016, 32(2):222-228.
[11] WYDE P R, WILSON S Z, KRAMER M J, et al. Pulmonary deposition and clearance of aerosolized interferon[J]. Antimicrob Agents Chemother,1984,25(6):729-734. doi:  10.1128/AAC.25.6.729
[12] MAASILTA P, HALME M, MATTSON K, et al. Pharmacokinetics of inhaled recombinant and natural alpha interferon[J]. Lancet,1991,337(8737):371.
[13] 陈泳伍, 唐丽琴, 张圣雨, 等. α干扰素雾化治疗在新型冠状病毒肺炎中的合理使用及药学监护[J]. 中国医院药学杂志, 2020, 40(6):632-635.
[14] 边原, 王玥媛, 杨勇, 等. 新型冠状病毒感染性肺炎抗病毒药物合理使用与药学监护[J]. 医药导报, 网络首发时间, 2020-02-03, 网络首发地址: http://kns.cnki.net/kcms/detail/42.1293.r.20200203.1003.002.
[15] 申昆玲, 尚云晓, 张国成, 等. α干扰素在儿科临床合理应用专家共识[J]. 中华实用儿科临床杂志, 2018, 33(17):1301-1308. doi:  10.3760/cma.j.issn.2095-428X.2018.17.006
[16] WANG Y, TIAN D L, SUN YY, et al. Pharmaceutical care for children in therapy of novel coronavirus pneumonia[J]. Chin J Hosp Pharm,2020(6):1-4.
[17] 国务院联防联控机制. 国务院联防联控机制新闻发布会 [EB/OL]. (2020-02-15) 2020-02-17]. http://www.Gov.cn/xinwen/gwylflkjz16/index.html.
[18] WANG M L, CAO R Y, ZHANG L K, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Res,2020,30(3):269-271. doi:  10.1038/s41422-020-0282-0
[19] THOMÉ R, LOPES S C, COSTA F T, et al. Chloroquine: modes of action of an undervalued drug[J]. Immunol Lett,2013,153(1-2):50-57. doi:  10.1016/j.imlet.2013.07.004
[20] SALATA C, CALISTRI A, PAROLIN C, et al. Antiviral activity of cationic amphiphilic drugs[J]. Expert Rev Anti Infect Ther,2017,15(5):483-492. doi:  10.1080/14787210.2017.1305888
[21] SCHREZENMEIER E, DÖRNER T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology[J]. Nat Rev Rheumatol,2020,16(3):155-166. doi:  10.1038/s41584-020-0372-x
[22] TAYLOR W R, WHITE N J. Antimalarial drug toxicity: a review[J]. Drug Saf,2004,27(1):25-61. doi:  10.2165/00002018-200427010-00003
[23] CHATTOPADHYAY R, MAHAJAN B, KUMAR S. Assessment of safety of the major antimalarial drugs[J]. Expert Opin Drug Saf,2007,6(5):505-521. doi:  10.1517/14740338.6.5.505
[24] MACKENZIE A H. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials[J]. Am J Med,1983,75(1A):40-45.